Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $15.51 USD
Change Today -0.50 / -3.12%
Volume 119.6K
CNCE On Other Exchanges
As of 9:53 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

concert pharmaceuticals inc (CNCE) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/17/15 - $18.29
52 Week Low
08/4/14 - $7.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

concert pharmaceuticals inc (CNCE) Related Businessweek News

No Related Businessweek News Found

concert pharmaceuticals inc (CNCE) Details

Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, genetic diseases, renal disease, inflammatory disease, and cancer. The company’s clinical-stage product candidates include AVP-786, which is in Phase II clinical trial for the treatment of neurologic and psychiatric disorders, including pain, behavioral disorders, mood disorders, and movement disorders; CTP-499 that is in Phase II clinical trial for chronic kidney disease in patients with type 2 diabetes; and CTP-354, which is in Phase I clinical trial to spasticity associated with spinal cord injury and multiple sclerosis. It is also developing CTP-730 that is in Phase I clinical trial for the treatment of inflammation or cancer; and JZP-386, which is in Phase I clinical trial to treat cataplexy and excessive daytime sleepiness. The company has collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sàrl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

55 Employees
Last Reported Date: 03/2/15
Founded in 2006

concert pharmaceuticals inc (CNCE) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $409.6K
Chief Financial Officer
Total Annual Compensation: $379.4K
Chief Operating Officer
Total Annual Compensation: $329.7K
Senior Vice President and General Counsel
Total Annual Compensation: $295.4K
Compensation as of Fiscal Year 2014.

concert pharmaceuticals inc (CNCE) Key Developments

Concert Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Concert Pharmaceuticals reported consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company's net loss applicable to common stockholders widened to $9 million from $7 million while on a per-share basis, the loss narrowed to $0.48 from $0.76 amid a much higher share count. Revenue also fell to $1.3 million from $1.6 million. Loss from operations was $8.8 million compared to $6.5 million for the same period of last year.

Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc. announced results from the recently completed Phase 1 clinical study of JZP-386, a deuterium-containing analog of sodium oxybate. The Phase 1 study evaluated the safety, pharmacokinetics and pharmacodynamics (PD) of JZP-386 in 30 healthy volunteers. Clinical data from this Phase 1 study demonstrated that JZP-386 provided favorable deuterium-related effects, including higher serum concentrations and correspondingly increased PD effects at clinically relevant time points compared to Xyrem® (sodium oxybate) oral solution. The safety profile of JZP-386 was similar to that observed with Xyrem. While the companies have determined that the deuterium-related effects observed in the Phase 1 studies do not support advancing into a later-stage clinical trial of JZP-386 at this time, the results indicate that further evaluation of JZP-386 is warranted. Accordingly, the companies intend to explore formulation options to enhance the positive effects observed in the studies to achieve an improved product profile for patients with narcolepsy. Sodium oxybate is the active ingredient in Xyrem, a prescription medicine marketed in the United States by Jazz Pharmaceuticals to treat cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy, a serious neurological disorder that affects approximately 1 in 2,000 people in the United States.

Concert Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 08, 2015

Concert Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 9:00 AM, Eastern Standard Time on May 08, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CNCE:US $15.51 USD -0.50

CNCE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CNCE.
View Industry Companies

Industry Analysis


Industry Average

Valuation CNCE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.4x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONCERT PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at